Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 6/20 | 0.45 |
| ▸ | KIT | P10721 | 10/20 | 0.45 |
| ▸ | KDR | P35968 | 2/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | CSF1R | P07333 | 1/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.45 |
| ▸ | FLT1 | P17948 | 1/20 | 0.45 |
| ▸ | FLT4 | P35916 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 9/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3112394 | 0.89 | KDR (0.54) | RXFP1KDRAURKARPS6KB1AURKB | |
| SCHEMBL4032759 | 0.87 | HDAC1 (0.49) | RXFP1KITKDRABL1EGFR | |
| SCHEMBL5900593 | 0.86 | KDR (0.54) | RXFP1KITKDRABL1EGFR | |
| SCHEMBL1011645 | 0.86 | RXFP1 (0.48) | RXFP1KITKDRABL1EGFR | |
| SCHEMBL5900455 | 0.84 | RXFP1 (0.47) | RXFP1KITKDRABL1EGFR | |
| SCHEMBL1041264 | 0.84 | KDR (0.64) | RXFP1KITKDRABL1EGFR | |
| Hydrochloric Acid SCHEMBL4036310 | 0.84 | RXFP1 (0.47) | RXFP1KITKDRABL1EGFR | |
| SCHEMBL4037710 | 0.82 | RXFP1 (0.51) | RXFP1KITKDRABL1EGFR | |
| SCHEMBL1039583 | 0.82 | RXFP1 (0.68) | RXFP1KITKDRABL1EGFR | |
| SCHEMBL1041884 | 0.81 | RXFP1 (0.48) | RXFP1KITKDRABL1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060128684-A1 | Anthranilic acid amide derivatives and their pharmaceutical use | BOLD GUIDO | 2006-06-15 | — | — | US | claimed |
| EP-1446382-B1 | ANTHRANILIC ACID AMIDES AND THEIR USE AS VEGF RECEPTOR TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-01-26 | — | — | EP | disclosed |
| EP-1446381-B1 | ANTHRANILIC ACID AMIDES AND PHARMACEUTICAL USE THEREOF | NOVARTIS AG (CH) | 2011-01-05 | — | — | EP | disclosed |
| EP-2269988-A2 | Anthranilic acid amides and pharmaceutical use thereof | Novartis AG (CH) | 2011-01-05 | — | — | EP | disclosed |
| EP-1572686-B1 | ANTHRANILIC ACID AMIDE DERIVATIVES AND THEIR PHARMACEUTICAL USE | NOVARTIS AG (CH) | 2009-04-15 | — | — | EP | disclosed |
| US-7482369-B2 | Anthranilic acid amides and their use as VEGF receptor tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2009-01-27 | — | — | US | disclosed |
| US-7091224-B2 | Anthranilic acid amides and their use as VEGF receptor tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2006-08-15 | — | — | US | disclosed |
| US-20060178409-A1 | Anthranilic acid amides and their use as VEGF receptor tyrosine kinase inhibitors | BOLD GUIDO | 2006-08-10 | — | — | US | disclosed |
| US-20060128684-A1 | Anthranilic acid amide derivatives and their pharmaceutical use | BOLD GUIDO | 2006-06-15 | — | — | US | disclosed |
| US-20050096356-A1 | Anthranilic acid amides and their use as vegf receptor tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2005-05-05 | — | — | US | disclosed |
| US-20040248947-A1 | Anthranilic acid amides and pharmaceutical use thereof | NOVARTIS AG (CH) | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178409-A1 | Anthranilic acid amides and their use as VEGF receptor tyrosine kinase inhibitors | AXL, FLT1, KDR | RXFP1 113/4885KIT 994/4885KDR 3/4885 |
| US-20040248947-A1 | Anthranilic acid amides and pharmaceutical use thereof | AFF1, FFAR1, FFAR2 | RXFP1 317/4885KIT 4113/4885KDR 847/4885 |
| US-20060128684-A1 | Anthranilic acid amide derivatives and their pharmaceutical use | AADAC, AADAT, NAAA | RXFP1 2090/4885KIT 3508/4885KDR 4663/4885 |
| US-20050096356-A1 | Anthranilic acid amides and their use as vegf receptor tyrosine kinase inhibitors | AXL, FLT1, KDR | RXFP1 165/4885KIT 838/4885KDR 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.